Holen Sie sich die Stockscreener-App
28.63
4.37%
1.20
Handel nachbörslich:
28.82
0.19
+0.66%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$27.43
Offen:
$27.64
24-Stunden-Volumen:
1.31M
Relative Volume:
0.76
Marktkapitalisierung:
$4.73B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$333.35M
KGV:
14.68
EPS:
1.95
Netto-Cashflow:
$315.22M
1W Leistung:
+7.83%
1M Leistung:
-5.45%
6M Leistung:
-20.47%
1J Leistung:
+8.32%
1-Tages-Spanne:
$27.51
$28.73
1-Wochen-Bereich:
$26.07
$28.73
52-Wochen-Spanne:
$25.56
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Vergleichen Sie ALKS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
28.63 | 4.53B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
152.44 | 66.38B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.20B | 29.96B | 957.25M | 5.31B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.99B | 14.26B | 1.98B | 0 | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 19.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.63B | 2.99B | 1.21B | 1.13B | 25.06 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2025-06-17 | Hochstufung | UBS | Neutral → Buy |
| 2025-05-28 | Eingeleitet | Needham | Buy |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Hochstufung | UBS | Sell → Neutral |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-11-05 | Hochstufung | Stifel | Hold → Buy |
| 2024-06-17 | Eingeleitet | TD Cowen | Buy |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-20 | Herabstufung | UBS | Neutral → Sell |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Live Scanner Shows Breakout on Alkermes plcMarket Surge Signal for Swing Traders Triggered - metal.it
Is Alkermes plc in a long term uptrendWealth Leverage Stock List - mustnews.co.kr
BlackRock increases stake in Alkermes to 17% - Investing.com India
BlackRock increases stake in Alkermes to 17% By Investing.com - Investing.com Canada
Alkermes plc Included in Top Momentum ScanInvestment Strategy Designed for Capital Protection - metal.it
Chondrosarcoma Market: Epidemiology, Pipeline Products, - openPR.com
Alkermes plc Announces Pricing of New Term Loans - AOL.com
What markets is AAON Inc. expanding into Is Alkermes plc stock a good long term investment optionBuild a diversified portfolio for steady growth - Jammu Links News
What is the dividend policy of Alkermes plc stockUnmatched market gains - Jammu Links News
Is Alkermes plc a growth stock or a value stockInvest smarter with expert trading signals - Jammu Links News
What makes Alkermes plc stock price move sharplyInvest confidently with professional advice - Jammu Links News
Is Alkermes plc stock overvalued or undervaluedGet exclusive access to expert stock recommendations - Jammu Links News
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales - MSN
What catalysts could drive Alkermes plc stock higher in 2025Invest confidently with professional advice - Jammu Links News
Should I hold or sell Alkermes plc stock in 2025Get expert analysis on top stock picks - Jammu Links News
Needham & Company LLC Reaffirms "Buy" Rating for Alkermes (NASDAQ:ALKS) - MarketBeat
How does Alkermes plc generate profit in a changing economyBuild capital through low-risk investments - Jammu Links News
What are analysts’ price targets for Alkermes plc in the next 12 monthsAchieve rapid portfolio growth with expert guidance - Jammu Links News
What are the technical indicators suggesting about Alkermes plcDiscover investment plans that deliver results - Jammu Links News
How strong is Alkermes plc company’s balance sheetUnlock powerful portfolio optimization tools - Jammu Links News
What markets is Alkermes plc expanding into Is ASLE stock a good long term investment optionBuild a portfolio that outperforms consistently - Jammu Links News
Alkermes Reports Q2 2025 Financial Results, Reiterates Expectations and Highlights Positive Clinical Study Results - AInvest
ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire
Alkermes shares climb 5% following Q2 earnings and revenue beat - MSN
(07/31/25) ALKS: Positive Narcolepsy Drug Trial Puts this Biotech Name in F - moneyshow.com
Alkermes anticipates record proprietary product sales above $1B for 2025 as orexin pipeline advances - MSN
Alkermes: A More Than Solid Quarter (NASDAQ:ALKS) - Seeking Alpha
Alkermes stock price target raised to $42 from $40 at RBC Capital - Investing.com Nigeria
Alkermes plc (NASDAQ:ALKS) Q2 2025 Earnings Call Transcript - Insider Monkey
Alkermes Beat Expectations With A Strong Second Quarter - Finimize
Schizophrenia Drugs Market Exclusive Report with Detailed - openPR.com
RBC Raises Price Target on Alkermes to $42 From $40, Keeps Sector Perform Rating - MarketScreener
Alkermes PLC (ALKS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Alkermes: Q2 Earnings Snapshot - Norwalk Hour
Alkermes Reports Strong Q2 2025 Financial Results - TipRanks
Trading Bots Trigger Alerts on Alkermes plc ActivityDaily Smart Money Movement Monitor Activated - metal.it
Multi Factor Analysis Ranks Alkermes plc as Strong BuyAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it
Alkermes Earnings Call: Strong Growth and Promising Trials - TipRanks
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018ALKS - ACCESS Newswire
Alkermes price target lowered to $33 from $35 at BofA - TipRanks
Why Alkermes plc stock attracts strong analyst attentionScalable Portfolio Growth Suggestions Released - metal.it
Alkermes Q2 2025 Earnings Call Transcript - MarketBeat
Published on: 2025-07-29 17:34:19 - metal.it
Alkermes (ALKS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Alkermes plc. SEC 10-Q Report - TradingView
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):